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Abstract
Randomised controlled trials (RCTs) are generally regarded as the gold standard for evaluating health care
interventions. The level of uncertainty around a trial’s estimate of effect is, however, frequently linked to how
successful the trial has been in recruiting and retaining participants. As recruitment is often slower or more difficult
than expected, with many trials failing to reach their target sample size within the timescale and funding originally
envisaged, the results are often less reliable than they could have been. The high number of trials that require an
extension to the recruitment period in order to reach the required sample size potentially delays the introduction
of more effective therapies into routine clinical practice. Moreover, it may result in less research being undertaken
as resources are redirected to extending existing trials rather than funding additional studies.
Poor recruitment to publicly-funded RCTs has been much debated but there remains remarkably little clear
evidence as to why many trials fail to recruit well, which recruitment methods work, in which populations and
settings and for what type of intervention. One proposed solution to improving recruitment and retention is to
adopt methodology from the business world to inform and structure trial management techniques.
We review what is known about interventions to improve recruitment to trials. We describe a proposed business
approach to trials and discuss the implementation of using a business model, using insights gained from three
case studies.
Introduction
Randomised controlled trials (RCTs) are widely accepted
as the gold standard for evaluating health care interven-
tions [1,2]. Several factors contribute to the success of a
RCT, including a research question that is relevant to
those at whom the trial results are aimed [3,4], a design
that is both scientifically rigorous and which fits in with
clinical practice [5], obtaining the appropriate legislative
approvals [6], the active participation and commitment
[7] of clinical sites/practices, appropriate analysis and/or
reporting and of course the willingness of individuals to
take part. Each of these stages can individually or collec-
tively be barriers to the successful delivery of a trial.
One of the most common problems, however, is with
recruitment. Many studies fail to meet their recruitment
targets, or fail to meet them without extending the
length of the trials. McDonald et al [8], for example,
found that of 114 trials, only 38 (31%) achieved their
original recruitment target and 65 (53%) were extended.
The reasons why certain trials recruit well while
others do not remain unclear [5]. Several potential limit-
ing factors have been identified in the literature includ-
ing constraints on clinician time [9.10], lack of available
staff [11], impact on clinician autonomy, complexity of
trial procedures [12], overestimating the number of
patients available for study participation [13] and the
perceived relevance of the research question to the clini-
cians [4]. Barriers to patients’ involvement include lack
of knowledge and trust in trials and unacceptability of
randomisation [14].
A recent systematic review of interventions to improve
recruitment to randomised controlled trials identified 27
eligible healthcare trials, including over 26,604 partici-
pants [15]. There were 24 studies involving interventions
aimed directly at trial participants, while three evaluated
interventions aimed at those recruiting participants.
Many studies looked at recruitment to hypothetical
trials and it is unclear how applicable these results are
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increasing recruitment: telephone reminders to non-
respondents following a written invitation to take part
in a trial (RR 2.66 95% CI 1.37 to 5.18), use of opt-out,
rather than opt-in, procedures for contacting potential
trial participants (RR 1.39 95% CI 1.06 to 1.84) and
open designs where participants know which treatment
they are receiving in the trial (RR1.25 95% CI 1.18 to
1.34).
An earlier systematic review with slightly different
inclusion criteria [16] came to similar conclusions,
although it also reported monetary incentives and cultu-
rally sensitive trial materials to be effective. Both reviews
found the literature on the effect of recruitment inter-
ventions to be both sparse and often of poor methodo-
logical quality.
There are a number of proposals to increase recruit-
ment to trials. Campbell et al [17] agreed that, to be
successful, trialists should base their design on respect-
ing the needs of patients and clinical professionals.
Sackett [7] also described how, in multi-centre RCTs, a
responsibility of each site should be to involve and train
those who will be recruiting and following-up trial parti-
cipants. He stated that such action would enable colla-
borators to ‘buy-in’ to the trial and develop both
ownership and commitment, terms more familiar in the
business world than in health research.
One proposed solution to improving recruitment and
retention is to adopt methodology from the business
world to inform and structure trial management techni-
ques [18]. Francis et al [18] developed a reference model
(developed from marketing theory), which could be used
for improving trial processes and as such, potentially
improve recruitment to trials. However, whether this
approach is useful in practice remains unclear.
This paper, therefore, seeks to a) describe the pro-
posed business approach to trials and b) discuss the
implementation of a business approach using insights
gained from three case studies.
A business approach
Francis et al [18] first discussed whether clinical trials
could be regarded as businesses and suggested that
dimensions of running a successful trial include ‘market-
ing’, ‘sales’ and ‘ongoing client management’ which
require a range of effective management techniques par-
alleling those for running a successful business. Francis
et al used multiple methods to develop a reference
model using insights from marketing theory, which
could be used for ongoing assessment of the sales and
marketing capability of a trial. The model has four
domains: (1) Building Brand Values (2) Product and
Market Planning (3) Making the Sale and (4) Maintain-
ing Engagement. Each of the four domains has three
components (see Figure 1). The twelve components are
considered as links in a chain; if one link is underdeve-
loped then the whole chain is weakened. Table 1
includes our translation of the model into language that
trialists are more familiar with.
Francis et al proposed that the model could be used in
a variety of ways to help the conduct of clinical trials.
These included: (1) to guide development of a recruit-
ment plan, (2) as a diagnostic tool if trials have difficul-
ties (and hence as a basis for deciding what type of
remedial action to take), and (3) for auditing the pro-
gress of trials (to enable early identification of weaker
managerial components and allow initiatives to
strengthen them to be developed). As the model was
developed from a theory-building process and only from
a single trial, it was proposed as a tentative framework,
a n dt h u se v i d e n c ei sr e q u i r e df r o mar a n g eo ft r i a l st o
validate its findings.
To that end, we present below three case studies
where the model was applied (these case studies repre-
sent trials known to the authors that had used the
model). Each case study represents a slightly different
use of the model, highlighting its versatility in the trials
arena.
Implementation of the business model
Case study 1: the CRASH-2 trial (using the model to develop
trial processes)
CRASH-2 is a large multinational randomised placebo
controlled trial among trauma patients with, or at risk
of, significant haemorrhage, to investigate the effects of
antifibrinolytic treatment on death and transfusion
requirement [19]. Recruitment commenced in May 2005
and was completed successfully in January 2010. In the
set up phase of this trial, which aimed to recruit 20,000
trauma patients within 4.5 years, the business model
developed by Francis et al [18] was applied to plan the
overall trial management. Below we illustrate in detail
how the twelve components of the model were used to
guide the management of the trial.
Developing brand values
The ‘CRASH’ brand was already established with some
patient organisations and several hundred emergency
and critical care doctors worldwide following the suc-
cessful delivery of the CRASH trial [20]. At the end of
the CRASH trial 50 key collaborators were asked about
the reasons they took part in the trial and what aspects
of the trial coordinating centre’s performance they
would like to see improved. This information allowed
the CRASH-2 coordinating team (the same team as ran
the CRASH trial) to identify both the positive aspects
and weaknesses of the CRASH ‘brand’. Overall, the col-
laborators viewed their association with the CRASH trial
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continued use of the original ‘CRASH’ theme in the
logo and acronym for the CRASH-2 trial was considered
useful to build on the positive image already established.
Gaining legitimacy and prestige
Factors which were identified by CRASH trial collabora-
tors as giving the trial legitimacy and prestige were
enshrined into the CRASH-2 trial. These factors
included trial coordination by an academic institution,
funding by a non-commercial organisation and manage-
ment and overview by respected individuals in the rele-
vant clinical and academic fields. Obtaining approval
from all relevant ethics and regulatory agencies is
required legally but this was also important for assuring
collaborators about the ethical aspects of the trial and
its compliance with relevant local legal requirements. In
addition, approval for the trial was obtained from the
World Health Organisation Ethics Committee as this
was considered a positive ‘tag’ from a relevant presti-
gious organisation when marketing the trial globally. It
was important to consider who the collaborating investi-
gators viewed as ‘prestigious’ individuals and institu-
tions’ and engagement of these was maintained
throughout the course of the trial.
Signalling worthiness
Recognising that even the simplest of trials would
increase the workload for clinicians and their teams, the
CRASH-2 trial utilised a simple pragmatic design and the
trial-related procedures were kept to a minimum.
CRASH-2 also emphasised the values that would appeal
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Figure 1 The business model. Illustrates the four domains of the model and the three components of each domain (from Francis et al [18]).
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Component Component description How this translates for trialists
1a. Developing brand
values
’Brand values’ define what a ‘brand ‘is’ and what it ‘is not’ -
i.e. its ‘personality’.
The ‘brand’ needs to convey clearly what a trial ‘stands for’;
what collaborators and participants can expect as being
part of your study.
1b. Gaining legitimacy
and prestige
Trials need legitimacy - they need to be positively ‘tagged’
by association with prestigious individuals and institutions.
At every stage in the trial demonstrate that the trial is
being professionally managed. The support of respected
funding bodies, Universities, clinical networks, academics
and clinicians all contribute to this component.
1c. Signalling worthiness It is vital to signal to collaborators and participants that this
trial will create greater value than the costs (time and
money) involved.
Demonstrate that the research question is extremely
important. Can the trial be supported at recruiting sites by
networks and/or research money? What benefits may
participation and outcome bring to knowledge of the best
treatments?
2a. Providing simple,
complete processes
Trials require clinical staff to undertake work that is
additional to their normal duties.
Getting a trial set-up, identifying, and recruiting participants,
delivering the trial intervention and follow-up of
participants all require effort. Data collection should be the
minimum required and data entry/transfer processes should
be as simple as possible. Clarity re roles and responsibilities
is vital.
2b. Devising strategies
for overcoming
resistance
Potential participants frequently raise objections. Recognise what anxieties collaborators are likely to have
and develop accurate, standard responses. Ensure that the
science of the trial is clear and unambiguous.
2c. Adopting an explicit
marketing plan
The marketing of a trial is too important to be done
informally. A formal marketing plan is required and should
include a definition of target market segments (groups that
need to buy in to the trial) and the trial’s unique selling
points (USPs).
Consider who the gatekeepers are and who should be
approached to investigate participating in a study; consider
why involvement in this trial is unique and the importance
of answering the research question.
3a. Engaging active
sponsors, champions
and change agents
’Selling’ a trial to prospective participants requires
persuasion. This requires enrolling sponsors (public
advocates), champions (activists) and change agents
(facilitators).
Obtain and maintain the support of multiple groups such
as disease specific networks, local experts in the disease
area (e.g. local lead clinicians who can promote the study in
their area), patient representatives and trial managers.
Involve local investigators in promoting the study by giving
presentations about the trial.
3b. Delivering a multi-
audience, multi-level
message
Trials need to convey sales messages through publicity,
presentations, training materials, etc.
Communicate in the language of the persons being
targeted (e.g. surgeons are more likely to be persuaded by
different messages to administrators or nursing staff).
Correct any misunderstandings by inviting feedback from
audiences that the trial has been presented to and
adapting the information as appropriate.
3c. Achieving buy-in (in
public)
Public buy-in requires intended participants to announce
their commitment to join the trial. When someone states, in
public, that they are willing to undertake an action, then
they are much more likely to do it.
Through websites, newsletters and other communication
means, create and regularly update information on
participating collaborators. Ensure that local teams are
aware of research going on that may involve patients they
deal with (e.g. ward staff). The local clinical leads should
inform colleagues and team members of their participation
in the trial enthusiastically and in person.
4a. Ensuring positive
‘moments of truth’
People judge organisations on the basis of their experience
at ‘moments of truth’.
Have systems in place (e.g. dedicated email accounts,
frequently asked questions on the trial website, prompt
response by the trial manager to queries) to ensure all
communications are handled efficiently and honestly.
Providing competent and honest responses will increase
loyalty to the trial and the research team and will result in a
greater chance of ongoing successful collaborations.
4b. Providing frequent
positive reinforcement
Positive reinforcement for existing participants should be an
important part of a trial’s ‘participant retention strategy’.I ti s
more ‘expensive’ to recruit new participants than to retain
existing participants.
Provide regular updates of information and recognise
successes. Keep participants informed e.g. through regular
newsletters, website updates etc and sending small tokens
of appreciation.
4c. Facilitating
incorporation into
routines
Activities that become embedded as routines are more
likely to be done than ‘one-offs’.
As far as possible, ensure the trial procedures are simple, in
order that the participating sites can incorporate the study
into their established routines. Flexibility may be required as
processes can vary at different clinical sites.
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trial question, contribution of the trial to advancing med-
ical knowledge, how the trial might potentially influence
patients’ chances of survival in the future, positive aspects
of being part of a global network with a common focus,
potential for authorship or being named in the publica-
tion, potential to improve career prospects through being
part of a research collaboration and ‘hands-on’ experi-
ence on how a trial is organised and conducted.
Providing simple, complete processes
The CRASH-2 trial identified and minimised those tasks
which could only be done by the collaborators at recruit-
ing sites (recruitment and follow-up of participants) and
maximised those which could be done by the trial coordi-
nating centre (TCC). For example, the TCC took respon-
sibility for completing and assembling documents for
ethics and regulatory application, liaising with ethics
committees as much as possible, responding to any com-
ments made and ensuring that reporting requirements
were fulfilled. Randomisation methods also took into
consideration local needs. For example, if international
telephone lines were not available, an alternative rando-
misation method was made available. Multiple methods
for data collection were also implemented taking into
consideration the availability of fax machines, internet
connection and computer software. Collaborators could
choose a data collection method most suitable for their
situation. All guidance on trial processes were made sim-
ple, translated into local languages where required and
were easily accessible in the site study file and on the
trial collaborators website. Without simplicity and com-
plete processes, the trial team recognised that buy in was
likely to be lower and the possibility of dropout from the
trial would be increased.
Strategies for overcoming resistance
Factors were identified that might cause a potential col-
laborator to reject the CRASH-2 trial or undertake it
with less than full commitment; for example colleagues
not being supportive of the trial, anxieties about putting
patients into a research trial, anxieties about how to
explain the trial to relatives, the amount of paperwork
involved, the lack of incentives for junior staff to recruit
and not remembering to recruit. In a concerted attempt
to address these issues directly, the TCC made training
presentations and responses to frequently asked ques-
tions available to collaborators.
Adopting an explicit marketing plan
A formal marketing plan was developed that included a
definition of target market segments i.e. groups that
needed to buy-in to the trial. The CRASH-2 trial needed
to engage a wide variety of people and organisations
including funders, academics, clinicians, nurses, adminis-
trators, ethics committees, regulatory agencies, partici-
pants and their relatives, patient organisations, academic
press and drug manufacturers. Each person/group had
varying levels of interest but involvement by each was
required for the success of the trial. The uninformed
needed to be told about the trial and this was done pri-
marily by providing simple information using a variety
of means including personal contacts, email, post, jour-
nal articles and advertising in the scientific press such as
the Lancet website. Those who still had concerns after
reading the information were contacted personally by
someone from the TCC or another individual likely to
be viewed as having legitimacy and prestige. Those who
were interested but slow to act were supported and
encouraged by the TCC and other collaborators (for
example a local national coordinator). Collaborators
who were recruiting well were highlighted in, for exam-
ple, trial newsletters and on the trial website. A number
of key collaborators were identified as being vital for the
success of the trial. For CRASH-2, they were the ones
w h od e m o n s t r a t e dt h a tt h e yc o u l dr e c r u i tal a r g en u m -
ber of the patient population required for the trial and
were able to ensure that data collection was of the high-
est quality. Many of these were engaged as national
coordinators for their countries and assisted in engaging
others to join the collaboration. They shared their
experience of the trial and its processes so others could
learn from them.
Engaging active sponsors, champions and change agents
In addition to clinical trialists understanding that a
sponsor is the person/institution taking responsibility
for the initiation, management and financing (or arran-
ging the financing) of a trial [21], sponsors can also be
considered as public advocates, champions as activists
and change agents as facilitators of research [18]. It is
also known that persuasion is more likely to occur if
the advocate is respected and known personally to the
prospective participant. For CRASH-2, this involved
engaging and maintaining the support of multiple
groups such as disease specific networks or societies,
experts in the disease area (e.g. local lead clinicians
who can promote the study in their area), patients and
their representatives. As an international trial, engaging
people within a country was required to ensure the
message was relevant to that country and sensitive to
their needs.
Delivering a multi-audience, multi-level message
For the CRASH-2 trial, multi-audience referred to the
different interest groups involved and multi-level
referred to that which “would appeal to the heart and
the head”. CRASH-2 needed to communicate in the
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doctors in general needed to be convinced by the
science of the trial and information on the scientific evi-
dence to support the conduct of the trial was crucial.
However, many nurses wanted to know more about the
potential benefits for patients to convince them to colla-
borate. Although the same information was being pre-
sented, at collaborators meetings for example, the key
messages needed to use language which addressed both
sets of concerns.
Achieving buy-in (in public)
The trial team recognised that the trial impacted on
more people at each site than solely the trial team. As
such, the TCC advised local collaborators to ensure that
local teams not directly involved in the trial, but who
may be involved in the care of a trial participant, were
aware of the trial, for example physiotherapists and
pharmacists. To ensure that there was commitment to
the trial, where possible (for example at collaborators
meetings), collaborators were asked to state their com-
mitment at the meeting because once someone states in
public that they are willing to undertake an action, they
are much more likely to actually do it [18].
Ensuring positive ‘moments of truth’
When collaborators needed to make contact, the
CRASH-2 team attempted to make all dealings with the
TCC positive. To enable this, the CRASH-2 trial devel-
oped systems such as dedicated email accounts, fre-
quently asked questions (FAQs) on the trial website,
ensured prompt response to queries and developed
in-house procedures to ensure all communications were
handled efficiently within set time frames. However,
there were times when TCC procedures failed and in
those circumstances an honest response, with an
apology and a clear plan to resolve the problem, was
given. The TCC believed that this was likely to be
viewed more positively than trying to pretend nothing
was wrong.
Providing frequent positive reinforcement
Many of the doctors and nurses in the local trial team
were involved in recruiting patients and completing the
necessary paperwork for the trial. Recognising and
rewarding these acts were seen as vital for them to con-
tinue to be motivated to deliver these tasks. Recognition
included issuing certificates of participation, sending
small tokens from the TCC after they recruited each
patient and sending personalised text messages to thank
them for their work. Also opportunities for networking,
social interaction and the sharing of experiences at col-
laborators meetings were necessary.
Facilitating incorporation into routines
CRASH-2 attempted to incorporate as many trial proce-
dures as possible within local routine. For example, trial
participants generally needed to have cross-matching for
blood transfusions; attaching a CRASH-2 trial label/logo
to all blood transfusion forms assisted the doctors/
nurses to remember the trial as part of their standard
care routine.
Case study 2: the TXT2STOP trial (using the model as a
diagnostic tool)
TXT2STOP is a trial of smoking cessation support via
text (sms) messages http://www.txt2stop.org/. The trial
had been informed by a pilot study which had success-
fully recruited 200 participants in 17 days. By the time
of recruitment to the full trial, however, the external
environment had changed dramatically with the intro-
duction of the “no-smoking in public places” policy
introduced in the UK and concurrent large-scale stop
smoking multi-media campaigns being run by the UK
National Health Service (NHS). This resulted in only
1056 participants being recruited to the trial in the first
eight and a half months (instead of the expected 2000
participants). At this time (June 2008), the business
model was used as a framework for understanding
approaches to increasing trial recruitment.
The model resulted in a new conceptualisation of
recruitment. According to the model the trial was being
promoted to three distinct groups (market segments) -
directly to smokers, primary care teams and smoking
cessation services. The trial team carried out a review of
the existing literature and spoke with members of each
group to identify what people in each of the selected
market segments would “value” (ie what would encou-
rage them to ‘sign-up’) and to identify anything that put
them off joining or recruiting to the trial. Text messages
and letters to potential participants were developed
focussing on the potential benefits of participation and
the factors that have been reported to encourage partici-
pants to join trials [22-27]. To ensure that the benefits
of involvement were not outweighed by costs to the
GPs, appropriate funding was secured via service sup-
port costs (attributed to the UK NHS) [28]. Letters were
written directly to smokers on GP lists so that the trial
was not reliant on GP or nurse clinical time telling
patients about the study. The value of the trial was
endorsed by stating University links in the letters. The
trial team engaged active sponsors and the trial was pro-
moted on the NHS smoking cessation websites in Eng-
land, Wales and Scotland. All promotion activities and
adverts were monitored to evaluate their time and
monetary costs and effectiveness. Cost-effective strate-
gies were repeated and less effective strategies aban-
doned or revised.
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4744 participants being recruited in the following 10
months and resulted in the trial being completed ahead
of schedule. The proportion of eligible participants join-
ing the trial also increased from 33% to 57%.
Case study 3: the LIFELAX trial - use of the model as an
audit tool
LIFELAX is a trial of diet and lifestyle vs laxatives in the
management of constipation in older people [29]. From
the outset, the trial team attempted to consider the trial
in business terms. The coordinating team identified
potential gains and benefits that would accrue from par-
ticipation in the trial and conveyed messages tuned to
the distinctive needs of target groups (nursing staff,
administrators etc) through presentations and training
materials. A marketing plan was developed and adopted,
which included the trial’s unique selling points. Recog-
nising there would be no direct material benefit for pri-
mary care doctors (general practitioners) in taking part,
the marketing strategy was targeted towards identifying
all potential gains and benefits that would accrue from
participating in the trial. Despite this approach, the trial
failed to recruit to target. In response to this the LIFE-
LAX coordinating team used the model as an audit tool
to retrospectively assess the recruitment strategies
adopted within the trial and to learn lessons for future
trials.
Using the model, the trial team identified that they
had failed in their early attempts to recruit public advo-
cates for the trial. It also identified that patient repre-
sentative activities were limited to involvement in the
Trial Steering Committee (TSC) only and would have
benefitted from wider involvement throughout the trial
processes. The team also believed that if they had
adopted techniques to increase awareness of the partici-
pating general practices this would have resulted in
greater support and commitment, eg through regular
publication of lists of participating practices.
Salient lessons from all three case studies are sum-
marised in Table 2.
Discussion
It is crucially important for a trial to recruit to its target
sample size. Poor recruitment can lead to an underpow-
ered study, which may result in clinically important
effects being missed (i.e. judged to be non-significant)
[30]. A non-significant finding increases the risk that an
effective intervention will be abandoned before its true
value is established, or that there will be a delay in
demonstrating this value while more trials or meta-ana-
lyses are done. Underpowered trials also raise an ethical
problem: trialists have exposed participants to an inter-
vention with uncertain benefit but may still be unable to
determine whether an intervention does more good
than harm on completion of the trial.
Often trialists apply for recruitment extensions to
achieve the desired sample size. This, however, invari-
ably adds to the cost of running trials and is likely to
result in delays to the results from these ongoing trials
being available to inform clinical practice. A further
consequence is that if more resources are diverted to
these “failing” trials, there is less money available to sup-
port new trials, which may result in less research being
undertaken [17].
The two reviews summarised in the paper highlight
the potential benefits of interventions such as the use of
opt-out, rather than opt-in, procedures for contacting
potential trial participants and greater use of open
designs where participants know which treatment they
are receiving in the trial. However, some of these strate-
gies have disadvantages, which may limit their wide-
spread use. For example, the use of opt-out procedures
remains controversial and the ethics of this approach
has been challenged [31]. The use of open designs may
also reduce the scientific rigour of the trial as, by defini-
tion, blinding is not adopted. However using an active
comparator rather than placebo may, on the other hand,
offer both recruitment and applicability advantages
[3,16].
In addition, evidence from the case studies presented
in this paper suggests that a marketing approach is
feasible in trials. In the TXT2STOP trial all the new
interventions and processes adopted fitted into the
marketing framework (tool) and a marked improve-
ment in recruitment followed. On first appraisal, there
is an apparent clash of values between business and
medicine - among key business values are profit and
competition, while among the traditional values of
health care researchers are service, advocacy, and
altruism. However, they share common goals; busi-
nesses strive to find customers and encourage them to
buy what is on offer, clinical trials strive to find doc-
tors and patients/volunteers and encourage them to
sign up and stay on board. One reason that appears to
contribute to an unwillingness to use marketing con-
cepts within clinical trials is that trialists are unfamiliar
with the business language and are unsure how to
translate these concepts into recognisable trial proce-
dures (personal communication). In an attempt to
address this, we have presented example ‘translations’
of the key concepts in Table 1.
It is also clear from the case studies that the terms in
the model have to be operationalised individually for
each trial. Market segments will be different for each
trial, as will the range of stakeholders. This, therefore,
requires extensive planning ahead of starting
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2.1: Case study one - using the model to develop trial processes
Domains and
Component
Issue Identified Action Taken
1. Building brand values
1a. Developing brand
values
Identify the key positive qualities which collaborators
associated with the successful delivery of the previous
CRASH trial (i.e. the ‘CRASH brand’).
Conducted a survey of key collaborators from the previous
trial to ascertain reasons for participation in that trial and
what aspects of the coordinating centre’s performance
could be improved. Identified that continued use of the
theme from the previous trial was useful to build on
positive image already established.
1b. Gaining legitimacy
and prestige
Need to enshrine the factors identified by the CRASH trial
collaborators into CRASH-2.
Trial was coordinated by an academic institution, funding
was by a non-commercial organisation and respected
individuals identified and engagement maintained
throughout CRASH-2.
1c. Signalling worthiness The trial increased workload for clinical teams and the need
to keep this to a minimum.
Simplified design and minimised procedures. Emphasized
the values of adding to the clinical evidence and
knowledge and prestige gained from individual participation
(e.g. training in trials/authorship potential).
2. Product and market planning
2a. Providing simple,
complete processes
Recognised that, to maximise recruiting site participation
and follow-up of participants, processes would have to be
simple.
Minimised tasks that require to be done at recruiting sites
and maximised those done by coordinating centre. Built in
flexibility to accommodate varying local needs.
2b. Strategies to
overcome resistance
Factors that may cause potential collaborator to reject or
not fully commit to CRASH-2 were identified.
Coordinating centre created training responses and
frequently asked questions were made available to
collaborators to address issues (e.g. how to explain the trial,
how to incentivise junior staff to recruit).
2c. Adopting an explicit
marketing plan
Need for a marketing plan and to engage with a wide
variety of people and organisations.
Developed a formal marketing plan including definition of
groups that needed to buy into the trial.
3. Making the sale
3a. Engaging active
sponsors, champions
and change agents
Need to recognise who the groups, networks and experts
in the disease area are.
Engaged and maintained support of groups such as disease
specific networks and patients and their representatives,
including within participating countries to ensure any local
sensitivities were addressed.
3b. Delivering a multi-
audience,
multi-level message
Different groups of people require the same information in
varying formats to address concerns.
Ensured that when the same information was being
presented to different groups (e.g. medical staff and nurses),
the key messages were presented in ways that addressed all
needs and concerns.
3c. Achieve buy-in (in
public)
Recognition that the trial impacted on many more people
at participating sites than the trial team and that a
confirmation of commitment made publically by
collaborators is more likely to result in their active
participation.
Local collaborators were asked to raise awareness of the trial
to anyone involved in the care of the trial participants.
Collaborators were invited to state their commitment to the
trial in public (e.g. at trial meetings).
4. Maintaining engagement
4a. Ensuring positive
‘moments of truth’
The need to be efficient, honest and timeous. The central coordinating team tried to ensure that all
collaborators had a clear and complete response to any
queries. Any failures in procedures were reported honestly,
with an apology and with a plan as to how to resolve any
problems.
4b. Providing frequent
positive
reinforcement
Many local team members (e.g. doctors and nurses) were
crucial contributors to ensuring the trial was successful at
their site.
Recognised and rewarded acts (e.g. completing trial
paperwork) by sending personalised texts, small tokens of
appreciation and certificates of participation. Enabled
networking and sharing of experiences.
4c. Facilitating
incorporation into
routines
As many trial procedures as possible should be
incorporated into local routine.
Supported this through provision of additional helpful
processes (e.g. providing trial labels to be attached to blood
transfusion forms) to assist clinical staff to remember the
trial as part of their standard care routine.
2.2: Case study two - using the model as a diagnostic tool
Domains and
Component
Issue Identified Action Taken
1. Building brand values
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1a. Developing brand
values
TXT2STOP set out to establish itself as a high quality trial as
reflected by the manner in which it dealt with participants.
Some participants hearing about the trial via adverts
reported concerns about the trial being a scam.
Team amended the way the trial was presented in
information to address this, paying particular focus to the
potential benefit of the intervention to the NHS if proven
effective and stating links to university.
1b. Gaining legitimacy
and prestige
A need to clarify that the trial was funded and endorsed by
a respected Institute.
The University links were stated in letters and other trial
documents. The trial was funded by a non commercial
institution.
1c. Signalling worthiness There was a need to ensure that the general practitioners
were not ‘out of pocket’ as a result of participating in the
trial.
Appropriate National Health Service support costs were
secured to support the general practitioners in order that
they were not financially compromised as a result of
participating in the trial. The importance of the trial
question and the potential benefit of the intervention to
the NHS, if proven effective were outlined in study
information.
2. Product and market planning
2a. Providing simple,
complete processes
Workload at the sites had to be reduced as much as
possible.
To facilitate recruitment and reduce the burden at recruiting
general practices, letters were sent directly to smokers on
the practice lists, thus negating the need for the doctors
and nurses to tell their patients about the trial.
2b. Strategies to
overcome resistance
It was necessary to identify what the benefits to each of
the participating groups were.
The central team identified what would encourage the main
participants (smokers, health care teams and smoking
cessation services) to participate.
2c. Adopting an explicit
marketing plan
Due to low recruitment figures during the early months of
recruitment the marketing strategy had to be reviewed.
Adverts for the trial were evaluated and only effective
adverts on effective media were repeated. We started to
market the trial to potential participants who had registered
interest but who had not gone on to either consent or not
consent to trial inclusion.
3. Making the sale
3a. Engaging active
sponsors, champions
and change agents
Clarity was required as to who the main gatekeepers were. Relationships were established with key gate keepers such
as the Scottish and English smoking cessation websites who
promoted the trial.
3b. Delivering a multi-
audience, multi-level
message
Appropriate wording and means of communication are
required.
Letters and text messages to potential participants were
worded to focus on the different motivations that smokers
may have for attempting to quit and joining a trial.
3c. Achieve buy-in (in
public)
There was a need to use different media sources to
indicate endorsement and promote the study.
The smoking cessation service research network distributed
information about the trial to all participating services.
4. Maintaining engagement
4a. Ensuring positive
‘moments of truth’
Being allocated to the control group was a difficult
experience for many participants.
We ensured that all research assistants involved in
randomisation were trained in how to respond to
participants’ disappointment (and at time anger). It was
acknowledged that being allocated to the control group
was disappointing but reinforced that being involved in the
trial would enable the intervention to be made publically
available for everyone, if proven effective.
4b. Providing frequent
positive reinforcement
Information provision requires not only to be regular but
effective.
The effectiveness of all promotions were monitored and
evaluated. Only effective strategies were repeated.
4c. Facilitating
incorporation into
routines
Clarity and ease of procedures were required. All new processes were incorporated into standard
operating procedures.
2.3: Case study three - using the model as an audit tool
Domains and
Component
Issue Identified Action Taken
1. Building brand values
1a. Developing brand
values
Recognition that the brand values are vital in clarifying
what the trial will deliver (to health care professionals’
patients etc).
Continue to use distinct messaging and appropriately
qualified professionals to develop trial brand.
1b. Gaining legitimacy
and prestige
Recognise the key and appropriate individuals and
institutions.
Ensure that it is obvious who the trial is associated with.
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should be explicitly accommodated within the timetable
for the trial. It is not clear how this planning phase
might be funded, although it is possible that this should
be included in the trial grant application.
Strengths and weaknesses
This is the first paper to our knowledge which has pre-
sented some empirical evidence on the implementation
o ft h eb u s i n e s sm o d e l .T h i si sas t r e n g t ho ft h ep a p e r
and provides useful evidence on the feasibility and
acceptability of the model to the trial community. How-
ever, our case studies were not selected randomly - all
were known to the authors as having attempted to
implement the model.
From our case studies it is not yet clear which ele-
ments of marketing strategies are most effective or
whether it is the adoption of a whole approach that is
important. It is also not known if the improvement in
recruitment would have occurred had ‘marketing strate-
gies’ not been adopted. For example, in TXT2STOP
many of the strategies to improve recruitment had been
initiated prior to referring to the marketing model
(although it was noted that all activities undertaken
fitted into the marketing framework). In addition, some
of the case studies we have presented that have used the
business model could be considered atypical as one
study involved healthy volunteers, while two other stu-
dies were led by a researcher who was very familiar with
the development and process of the business model.
Table 2 Implementation of the business model (Continued)
1c. Signalling worthiness Ensured that any monetary costs to clinical investigators
was reimbursed and provided training that would be
generalisable in the trial setting and beyond.
Roll out any training and information to all participating
clinicians at the end of trial so that the ‘value’ will be,
eventually, available to all.
2. Product and market planning
2a. Providing simple,
complete
processes
Assistance required with electronic queries to search for
patients.
Provide assistance with any issues and consider reviewing
protocol if necessary to amend and simplify processes.
2b. Strategies to
overcome resistance
Initial assumption that resistance to participation would be
low but barriers to participation were subsequently
identified.
Be open minded about resistance and devise strategies in
advance to overcome.
2c. Adopting an explicit
marketing plan
There is a need for a formal marketing plan. Identified trial’s unique selling points for each of the
categories in order to highlight benefits of involvement and
supporting study.
3. Making the sale
3a. Engaging active
sponsors, champions
and change agents
Public advocates and patient representatives require to be
on board the study from the outset and across a wide
range of activities.
Team had failed in early attempts to recruit public
advocates (GP champions, PCT R&D Staff) and it would have
been beneficial if patient representative activities had been
more extensive than only participation in the Trial Steering
Committee.
3b. Delivering a multi-
audience, multi-level
message
One size does not fit all with regard to communicating and
addressing motivation of different target groups.
Presentations (contents and style) were tailored to fit with
the target audience (e.g. family doctors, nurses, practice
managers).
3c. Achieve buy-in (in
public)
Collaborators who make a silent decision to commit to the
study forgot easily - it is necessary to get a senior person
within the institution to announce their participation and
support of the study to the rest of their team.
Collated anecdotal evidence that the lack of awareness in
general practices suggested that team support would have
been greater had the senior management announced
involvement. Also realised that techniques such as
publishing lists of signed up practices would have assisted
in signalling the commitment of those sites to the study.
4. Maintaining engagement
4a. Ensuring positive
‘moments of truth’
A clear and efficient system of handling queries is required
in order to ensure an accurate and timely response.
The team set up a dedicated ‘LIFELAX.queries@......’ email
address, which was checked routinely and messages passed
to the most appropriate team member for response.
4b. Providing frequent
positive reinforcement
There is a need to undertake training, including follow-up
training, at all sites.
The study team largely achieved this component, the result
being that sites which underwent training and became
active recruiting sites remained committed to the trial until
the end.
4c. Facilitating
incorporation into
routines
This aspect of the study was fairly difficult for LIFELAX as
the patient search was a one-off.
The central team attempted to demonstrate to the staff at
the participating general practice sites that the principles
and techniques of behaviour change taught in LIFELAX
could be incorporated into routine practice and should not
be seen as study specific training only.
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framework for conceptualising recruitment and for iden-
tifying where further interventions or changes in trial
process should be considered. The case studies suggest
t h em o d e lc a nb eau s e f u lt o o la n dt h a tt h e r em a yb ea
link between the use of the model and increased
recruitment.
Further research required
The use of the business model requires further empirical
evaluation. Further work is also required to develop a
manual or similar tool to operationalise the model con-
sistently from trial to trial. Further research into how
effective the model would be as a disaster recovery tool
would also enhance the evidence. If however, the find-
ings of our case studies are replicated in other arenas, it
is likely that we could conclude that use of the model
increases recruitment to trials.
Conclusion
Recruitment is a challenge for most trials, sometimes a
very significant one. Trialists use a variety of approaches
to support recruitment but empirical evidence on what
works, when and why is rather scarce. The business
model is a new approach to trial management and offers
something that has been lacking: a consistent framework
for planning and managing recruitment. The model
seems promising based on results from a small number
of case studies. What is needed now are more examples
of its use. If the early promise of the model was repli-
cated in other trials, especially those of trialists unin-
volved in the development of the model, this would
represent a major advance in the conduct and manage-
ment of clinical trials.
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